← brief for 2026-08-17 · Slowing decline

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Key takeaways

This is an extension study for patients who completed a previous trial of zigakibart. It will monitor long-term safety in adults with IgA nephropathy.

Who did this work

Run by Novartis Pharmaceuticals. Novartis Pharmaceuticals (Novartis Pharmaceuticals)
Sites: Colorado Kidney Care Nephrology · Nephrology Associates Of Central FL · University of Iowa Hospitals and Clinics · NY Nephrology · Icahn School of Medicine at Mount Sinai · Knoxville Kidney Center Pllc

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-17
https://clinicaltrials.gov/study/NCT06858319